CAR-T Meeting 2021 | EN-ACTI2NG program: from TCRs to CARs

Hisse M. van Santen, PhD, Centro Biologia Molecular Severo Ochoa, Madrid, Spain, discusses the EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of chimeric antigen receptor (CAR) and T-cell receptor (TCR) Interactions and Nanoscale Geometry) and the research currently being undertaken by students into CAR T-cells. Research in the EN-ACTI2NG program investigates key questions about CARs, such as how signaling works, how these cells can be improved and what makes some CARs better than others. Dr van Santen also outlines the benefits and insights students can gain into the medical research industry in Europe through the EN-ACTI2NG program. This interview took place during the 3rd European CAR T-cell Meeting.